

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Novo Nordisk A/S	08/03/2011
RECEIVING PARTY DATA	
Name:	Novo Nordisk HealthCare AG
Street Address:	Andreasstrasse 15
City:	Zurich
State/Country:	SWITZERLAND
Postal Code:	CH-8050
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	11911563
CORRESPONDENCE DATA	
Fax Number:	(609)987-5440
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	609-987-5800
Email:	nnipatent@novonordisk.com
Correspondent Name:	Novo Nordisk Inc.
Address Line 1:	100 College Road West
Address Line 4:	Princeton, NEW JERSEY 08540
ATTORNEY DOCKET NUMBER:	7007.204-US
NAME OF SUBMITTER:	Lori M. Klewin
Total Attachments: 2 source=7007.204-US, Formality - Documents, 8-AUG-2011, 1302#page1.tif source=7007.204-US, Formality - Documents, 8-AUG-2011, 1302#page2.tif	

CH \$40.00 11911563

501619331

PATENT
REEL: 026713 FRAME: 0946

AFFIRMATION OF ASSIGNMENT

WHEREAS, Novo Nordisk A/S, a corporation organized under the laws of Denmark, located at Novo Allé, DK-2880 Bagsvaerd, Denmark (hereinafter ASSIGNOR), has assigned its entire right and title to interest in certain patent applications and patents (listed in attached Exhibit A), and now wishes to register the transfer of ownership and/or control of these patents and patent applications to Novo Nordisk Health Care AG.

WHEREAS, Novo Nordisk Health Care AG, a Swiss corporation, located at Andreasstrasse 15, CH-8050 Zurich, Switzerland (hereinafter ASSIGNEE) has acquired and wishes to affirm, perfect, and make of record its entire right, title and interest in, to and under said patents and patent applications in the United States.

NOW, THEREFORE, ASSIGNOR hereby affirms the transfer to ASSIGNEE of all of the full and exclusive rights, titles and interests to said patents and patent applications in the United States and its territorial possessions and any and all Letters Patent or similar legal protections to be obtained from any patent application or patent included in such transfer or any continuation, division, reexamination, extension, or reissue thereof, for the full term or terms for which the same may be granted in the United States and its territorial possessions.


ASSIGNOR accordingly hereby authorizes and requests the United States Patent and Trademark Office to issue all such Letters Patent or similar rights arising from said applications, continuations, divisionals, reissues, reexaminations, or reissues thereof to ASSIGNEE, as assignee of the entire right, title and interest in, to, and under the same.



Novo Nordisk A/S
Kåre Schultz
Chief Operating Officer
Novo Nordisk A/S

3 AUGUST 2011
Date

3 AUGUST 2011
Novo Nordisk A/S



Date

Mads Krosgaard Thomsen
Chief Science Officer
Novo Nordisk A/S

/lake

EXHIBIT A

ATTORNEY DOCKET NO.	PUBLICATION NO.	FILING DATE	APPLICATION NO.
7007.204-US	US 2009/0306352	October 15, 2007	11/911,563